Ozempic vs Mounjaro
Two different molecules, both once-weekly, both for diabetes.
| Attribute | Ozempic | Mounjaro |
|---|---|---|
| Molecule | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Frequency | Once weekly injection | Once weekly injection |
| Format | Prefilled pen, injector-dialed dose | Prefilled single-dose pen |
| Monthly price (CAD) | $250–310/mo retail ($252 at Costco) | $280–550/mo by dose ($300 at 2.5/5mg, $420 at 7.5/10mg) |
| Approval / indication in Canada | Type 2 diabetes management | Type 2 diabetes management |
| Availability | Widely stocked, most pharmacies | Widely stocked, most pharmacies |
Two mechanisms, one weekly routine
Ozempic and Mounjaro are both approved in Canada for managing type 2 diabetes and both arrive as a once-weekly injection, but the molecules underneath are genuinely different. Ozempic's semaglutide acts on a single hormonal pathway, the GLP-1 receptor. Mounjaro's tirzepatide, made by Eli Lilly, acts on two — GLP-1 and GIP — which is why it's often described as a dual agonist. Trial data comparing the two classes has generally shown a larger average effect on blood sugar and weight with tirzepatide, though individual response varies considerably and a stronger average effect doesn't guarantee a stronger result for any one patient.
Because they're chemically distinct, they aren't interchangeable in the way that brand and generic versions of the same molecule are. Switching from one to the other is a real clinical decision, not a substitution, and it typically means restarting a dose-titration schedule from the beginning rather than picking up where the previous drug left off.
Pricing by dose tier, not a flat rate
Mounjaro's Canadian pricing is structured in dose tiers rather than a single number. Eli Lilly's list pricing effective from late December 2025 sets the lower starting doses (2.5mg and 5mg) around $300 a month, stepping up to roughly $420 for the 7.5mg and 10mg tiers, with the highest maintenance doses running toward $550. Ozempic's pricing is comparatively flatter across its dose range, generally landing between $250 and $310 depending on pharmacy and whether it's purchased through a lower-margin retailer like Costco.
That tiered structure matters for budgeting: a patient starting Mounjaro at a low dose may pay close to what they'd pay for Ozempic, but if their prescriber titrates upward for effect, the monthly cost can climb meaningfully higher than an equivalent step-up on semaglutide.
Coverage and formulary position
Both drugs sit in the diabetes-treatment category for most private and public formularies, so coverage tends to be more consistent for either drug than for weight-management-labelled products. Still, formulary tiers and step-therapy rules differ by insurer — some plans require a documented trial of an older, cheaper diabetes medication before either semaglutide or tirzepatide is approved for reimbursement, and it's worth confirming that requirement before assuming either drug will be covered from day one.
The verdict: questions to ask your doctor
The most useful question to bring to a diabetes-management appointment is why a prescriber would lean toward one mechanism over the other for your specific case — dual GIP/GLP-1 agonism and single-pathway GLP-1 agonism can produce different side-effect profiles and different magnitudes of blood-sugar or weight change, and that clinical judgment isn't something a price comparison can substitute for.
Ask, too, how your specific insurance plan tiers each drug and whether step therapy applies — a plan that requires trying a lower-cost diabetes medication first, or one that reimburses tirzepatide only at certain dose tiers, can change the real-world cost far more than the sticker price on either pen.
If cost predictability matters to you, ask your doctor how likely a dose increase is over the coming months, since Mounjaro's tiered pricing means an upward titration carries a real cost implication that a flatter-priced option like Ozempic doesn't share to the same degree.
Frequently asked
- Is Mounjaro stronger than Ozempic?
- Clinical trials comparing tirzepatide (Mounjaro) to semaglutide (Ozempic) have generally shown larger average reductions in blood sugar and body weight with tirzepatide, but individual results vary and a prescriber needs to weigh your specific health profile, not just trial averages.
- Can I switch directly from Ozempic to Mounjaro?
- They are different molecules, not interchangeable versions of the same drug, so a switch is a distinct prescribing decision that typically involves restarting a dose-titration schedule. This is a conversation for your doctor, not a pharmacy substitution.
- Why does Mounjaro have several different price points?
- Eli Lilly prices Mounjaro by dose tier rather than a flat monthly rate, so the cost rises as the prescribed dose increases, roughly from $300 a month at the lowest doses to around $550 at the highest.